ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Mitochondrial amyloid-beta peptide: Pathogenesis or late-phase development?
dc.contributor.author | Yan, Shirley ShiDu | |
dc.contributor.author | Xiong, Wen-Cheng | |
dc.contributor.author | Stern, David M. | |
dc.date.accessioned | 2014-07-22T16:18:36Z | |
dc.date.available | 2014-07-22T16:18:36Z | |
dc.date.issued | 2006-07-17 | |
dc.identifier.citation | Yan, Shirley ShiDu et al. (2006). Mitochondrial amyloid-beta peptide: Pathogenesis or late-phase development? Journal of Alzheimer's Disease 9(2):127-37. | |
dc.identifier.issn | 1387-2877 | |
dc.identifier.uri | http://hdl.handle.net/1808/14815 | |
dc.description | This is the publisher's version, also available electronically from http://iospress.metapress.com/content/8q4cf2u7gw6cllxt/?genre=article&issn=1387-2877&volume=9&issue=2&spage=127 | |
dc.description.abstract | Mitochondrial and metabolic dysfunction have been linked to Alzheimer's disease for some time. Key questions regarding this association concern the nature and mechanisms of mitochondrial dysfunction, and whether such changes in metabolic properties are pathogenic or secondary, with respect to neuronal degeneration. In terms of mitochondria and Alzheimer's, altered function could reflect intrinsic properties of this organelle, potentially due to mutations in mitochondrial DNA, or extrinsic changes secondary to signal transduction mechanisms activated in the cytosol. This review presents data relevant to these questions, and considers the implication of recent findings demonstrating the presence of amyloid-β peptide in mitochondria, as well as intra-mitochondrial molecular targets with which it can interact. Regardless of the underlying mechanism(s), it is likely that mitochondrial dysfunction contributes to oxidant stress which is commonly observed in brains of patients with Alzheimer's and transgenic models of Alzheimer's-like pathology. | |
dc.publisher | IOS Press | |
dc.relation.isversionof | http://iospress.metapress.com/content/8q4cf2u7gw6cllxt/?genre=article&issn=1387-2877&volume=9&issue=2&spage=127 | |
dc.subject | Respiratory chain complex | |
dc.subject | Alzheimer's disease | |
dc.subject | Neurodegeneration | |
dc.subject | Reactive oxygen species | |
dc.subject | Apoptosis | |
dc.title | Mitochondrial amyloid-beta peptide: Pathogenesis or late-phase development? | |
dc.type | Article | |
kusw.kuauthor | Yan, Shirley ShiDu | |
kusw.kudepartment | Pharmacology and Toxicology | |
kusw.oastatus | fullparticipation | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
-
Pharmacy Scholarly Works [299]